Related Experiment Video
Updated: Jun 8, 2026

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis
Annie Wai Yeeng Chai1, Yee Hua Tan1, Shiyin Ooi1
1Translational Cancer Biology Research Unit, Cancer Research Malaysia, Subang Jaya, Malaysia.
Significance:
Mechanistically guided drug repurposing has been made possible by systematically integrating pharmacologic and CRISPR-Cas9 screen data. Our study discovers the biomarker and cell death mechanisms underpinning sensitivity toward AZD5582, an antagonist of the inhibitor of apoptosis family protein. Our findings have important implications for improving future trial design for patients with OSCC using this emerging drug class.
Insights
Drug repurposing combined pharmacologic and CRISPR-Cas9 screening data to identify biomarkers and cell death mechanisms for AZD5582, an inhibitor of apoptosis protein antagonist. This advances treatment strategies for head and neck cancers.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Mechanistically guided drug repurposing offers a novel therapeutic strategy.
- Systematic integration of pharmacologic and CRISPR-Cas9 screening data enables discovery.
- Understanding drug sensitivity mechanisms is crucial for clinical application.
Purpose of the Study:
- To identify biomarkers and cell death mechanisms associated with sensitivity to AZD5582.
- To explore the potential of AZD5582 as a therapeutic agent.
- To guide future clinical trial design for head and neck cancers.
Main Methods:
- Utilized CRISPR-Cas9 screening to identify genetic dependencies.
- Integrated pharmacologic data with genetic screening results.
- Analyzed cell death pathways activated by AZD5582.
Main Results:
- Discovered specific biomarkers predictive of AZD5582 sensitivity.
- Elucidated the cell death mechanisms induced by AZD5582.
- Identified AZD5582 as a promising drug candidate for certain cancers.
Conclusions:
- Mechanistic insights from integrated screening data facilitate drug repurposing.
- AZD5582 demonstrates potential as a targeted therapy.
- Findings support the development of targeted therapies for head and neck cancers.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Caspases
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
TGF - β Signaling Pathway
NF-kB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...

